Global Transarterial Chemoembolization (TACE) Market Growth (Status and Outlook) 2023-2029

Global Transarterial Chemoembolization (TACE) Market Growth (Status and Outlook) 2023-2029

The global Transarterial Chemoembolization (TACE) market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Transarterial Chemoembolization (TACE) is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Transarterial Chemoembolization (TACE) is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Transarterial Chemoembolization (TACE) is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Transarterial Chemoembolization (TACE) players cover Questex, Siemens Healthcare GmbH, Bellicum Pharmaceuticals Inc., Boston Scientific, Cook Group, Hikma Pharmaceuticals, Nippon Kayaku, Novartis AG and Pfizer Inc., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

Trans-arterial Chemoembolization (TACE) is an interventional radiology procedure that delivers anti-cancer medication (chemotherapy) and embolizing materials directly into blood vessels feeding a malignant liver tumor. TACE is a two-pronged approach that can simultaneously limit the blood supply feeding a tumor in order to destroy cancerous cells (embolization) while the chemotherapy prevents further growth.Transarterial Chemoembolization (TACE) is a minimally invasive procedure in which chemotherapy and embolic agents are directly delivered to a cancerous tumour via its blood supply. The embolic agents are used to cut off the blood supply to the tumour without affecting the rest of the liver. Compared to receiving conventional chemotherapy, TACE allows for the maximum amount of chemotherapy agent to reach the tumour, while limiting the amount released into the bloodstream.

LPI (LP Information)' newest research report, the “Transarterial Chemoembolization (TACE) Industry Forecast” looks at past sales and reviews total world Transarterial Chemoembolization (TACE) sales in 2022, providing a comprehensive analysis by region and market sector of projected Transarterial Chemoembolization (TACE) sales for 2023 through 2029. With Transarterial Chemoembolization (TACE) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Transarterial Chemoembolization (TACE) industry.

This Insight Report provides a comprehensive analysis of the global Transarterial Chemoembolization (TACE) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Transarterial Chemoembolization (TACE) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Transarterial Chemoembolization (TACE) market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Transarterial Chemoembolization (TACE) and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Transarterial Chemoembolization (TACE).

This report presents a comprehensive overview, market shares, and growth opportunities of Transarterial Chemoembolization (TACE) market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Chemotherapeutic Agents
Radio Therapeutic Agents
Drug-eluting Particles
Others

Segmentation by application
Hospitals
Clinics
Cancer Research Centers

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Questex
Siemens Healthcare GmbH
Bellicum Pharmaceuticals Inc.
Boston Scientific
Cook Group
Hikma Pharmaceuticals
Nippon Kayaku
Novartis AG
Pfizer Inc.
Spectrum Pharmaceutical
Roche Holding AG
Celgene
Bayer AG
Merck & Co., Inc.
SingHealth

Please note: The report will take approximately 2 business days to prepare and deliver.